Litcius/Paper detail

Silencing long non-coding RNA HNF1A-AS1 inhibits growth and resistance to TAM of breast cancer cells via the microRNA-363/SERTAD3 axis

Ying Li, Ling Liu, Yidong Lv, Yanwu Zhang, Linlin Zhang, Haiyang Yu, Weifang Tian, Zhan Zhang, Shihong Cui

2021Journal of drug targeting22 citationsDOI

Abstract

Long non-coding RNAs (lncRNAs) can exert effects on drug resistance of cancer cells. This study investigated the role of lncRNA HNF1A-antisense 1 (HNF1A-AS1) in growth and Tamoxifen (TAM) sensitivity of breast cancer (BC) cells. HNF1A-AS1 expression was promoted in BC cells and tissues. BC cells with HNF1A-AS1 silencing were constructed to detect cell proliferation. TAM resistant cell line with HNF1A-AS1 silencing and parent cell line with overexpressed HNF1A-AS1 were constructed to measure drug resistance. Silencing HNF1A-AS1 reduced proliferation and TAM resistance of BC cells. The downstream microRNAs (miRs) of HNF1A-AS1 and its targets were figured out and their functions in TAM resistance of BC cells were identified. HNF1A-AS1 sponged miR-363 to promote SERTAD3 expression. Downregulation of miR-363 or upregulation of SERTAD3 stimulated TAM resistance of BC cells. The findings in vitro were reproduced in in vivo experiments. It could be concluded that silencing HNF1A-AS1 inhibited growth and drug resistance to TAM of BC cells through the miR-363/SERTAD3 axis and the inactivation of the TGF-β/Smad pathway.

Topics & Concepts

Gene silencingDownregulation and upregulationmicroRNACancer researchCell growthMCF-7BiologySmall interfering RNALong non-coding RNARNA interferenceTransfectionCancer cellCell cultureCell biologyCancerRNAGeneGeneticsHuman breastCancer-related molecular mechanisms researchMicroRNA in disease regulationRNA modifications and cancer